alexionnNEW HAVEN: Even as the company prepares to head north to a new headquarters in Boston, the New Haven portfolio of drugs continues to power ahead for Alexion Pharmaceuticals, Inc. [NYSE:ALXN].

Sales for the company’s lead drug Soliris continues to generate new sales, and Strensiq and Kanuma, both drugs acquired by the company have seen significant sales increases as well.

 Judith ANEW HAVEN: The revamping of Alexion’s [NYSE: ALXN] Board of Directors continues with, the appointment of Judith A. Reinsdorf, JD.

Reinsdorf until recently served as Executive Vice President and General Counsel of Johnson Controls International, a “global leader” in building products and technology, integrated solutions, and energy storage, following its merger in September 2016 with Tyco International, where she served as Executive Vice President and General Counsel from March 2007 until September 2016.

akariLONDON: The tiny [$36 million market cap] UK company and potential Alexion competitor Akari Therapeutics [Nasdaq:AKTX], completed its Phase II COBALT Trial of Coversin [a C5 complement inhibitor] in patients with Paroxysmal Nocturnal Hemoglobinuria PNH.

PNH and Hemolytic Uremic Syndrome (aHUS) are the rare conditions that drive Soliris sales of more than $3 billion annually for Alexion.

NEW HAVEN: Melinta Therapeutics, Inc. [NASDAQ:MLNT]baxdela, is launching intravenous and oral formulations of Baxdela™ [delafloxacin] for the treatment of adult patients with acute bacterial skin and skin structure infections [ABSSSI] in the US.

Melinta has previously announced partnership agreements to launch Baxdela in numerous countries across the world, the FDA approved Baxdela in June 2017.

According to the company “no dosage adjustments are required due to weight, hepatic impairment or mild-moderate renal impairment, there are no food effects, and there is minimal potential for drug interactions,” with the drug.

Deborah DunsireNEW HAVEN: In an additional move to address what the activist investor Elliot Management said was a lack of bioscience experience on the company’s board, Alexion Pharmaceuticals Inc. [NYSE:ALXN] has appointed Deborah Dunsire, M.D. to the board.

Dr. Dunsire has served as President and Chief Executive Officer of Millennium Pharmaceuticals, Inc. from 2005-2013, which was sold to Takeda Pharmaceutical. Prior to Millennium, Dunsire led the Novartis North America Oncology Business, which according to the company’s release “grew in revenues from $50 million to more than $2.2 billion,” during her tenure.

healhtcareinnovationNEW HAVEN:The BioScience Pipeline Program, funded by Connecticut’s Quasi government venture capital firm Connecticut Innovations [CI], awarded grants to eight projects from local innovators affiliated with Yale University, the University of Connecticut (UConn), and Quinnipiac University.

The BioScience Pipeline program was founded in September 2015 to “enhance biomedical commercialization by providing milestone-based funding of up to $30,000 per project. In its fourth award round, this $500,000 per year pilot program provides critical funding to interdisciplinary ventures for business strategy, market definition, and prototyping activities. Awarded projects were selected based on their potential to create economic value and transform human health,” according to the news release of the awards by CI.

Half of the awards went to projects in the “digital healthcare space”, two of which include wearables.

RiluzoleTabs USP 50mg 60ctNEW HAVEN: Biohaven Pharmaceutical Holding Company Ltd. [NYSE:BHVN] announced positive results of its bioequivalence study with BHV-0223, what it calls an “innovative sublingual [can be taken without swallowing] formulation of riluzole.”

The study was designed to demonstrate “pharmacokinetic equivalence” of the company’s drug sublingual BHV-0223 compared to the reference listed drug Rilutek (riluzole), which is currently the standard of care treatment for patients with Amyotrophic Lateral Sclerosis (ALS).

Topline results confirmed that sublingual BHV-0223 (40 mg) achieved bioequivalent exposures relative to Rilutek (50 mg). In the study, 138 healthy volunteers were administered BHV-0223 and Rilutek under fasted conditions.